@robertluper.bsky.social
Reposted
"Gilead's licensees reported issues they faced were related to lack of procurement systems in resource-limited countries, shortages of medical personnel and facilities, supply chain bottlenecks, shortage of diagnostics, and lack of funding due to absence of or delay with global regulatory reviews."
"Gilead will supply the drug at no profit until these manufacturers are able to fully support demand."
#lenacapavir
#lenacapavir
The US unofficial room document: Technology Transfer Case Study of Remdesivir from Gilead Sciences is expected to be discussed tomorrow. The future of Gilead's voluntary licensing program on lenacapvir is discussed on page 4. @unitaidngos.bsky.social @unitaidcommunities.bsky.social
March 20, 2025 at 8:15 PM
"Gilead's licensees reported issues they faced were related to lack of procurement systems in resource-limited countries, shortages of medical personnel and facilities, supply chain bottlenecks, shortage of diagnostics, and lack of funding due to absence of or delay with global regulatory reviews."
Reposted
"Gilead will supply the drug at no profit until these manufacturers are able to fully support demand."
#lenacapavir
#lenacapavir
The US unofficial room document: Technology Transfer Case Study of Remdesivir from Gilead Sciences is expected to be discussed tomorrow. The future of Gilead's voluntary licensing program on lenacapvir is discussed on page 4. @unitaidngos.bsky.social @unitaidcommunities.bsky.social
March 20, 2025 at 8:12 PM
"Gilead will supply the drug at no profit until these manufacturers are able to fully support demand."
#lenacapavir
#lenacapavir